TIZIANA LIFE SCIENCES LTD

Insider buying spikes at Tiziana Life Sciences—CEO and major shareholder pile on shares, hinting at undervaluation despite weak fundamentals. Learn why.

CEO Ivor Elrifi’s $1.00 buy of 667,000 Tiziana Life Sciences shares signals insider confidence in the company’s phase‑2a intranasal trial and a potential rally from its 52‑week low.

Insider buying of Tiziana Life Sciences shares signals confidence in its intranasal foralumab pipeline, suggesting a potential undervalued long‑term opportunity.

Insightful look at Tiziana Life Sciences insider holdings, CFO confidence, and Phase‑2 data that could lift stock above $2.60.

Investor insights: Tiziana Life Sciences insider options reveal bullish confidence in upcoming FDA milestones, yet potential dilution and valuation risks remain.